Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 2 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionRecruitingNCT06992440Phase 2
- Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 DiabetesRecruitingNCT06989723Phase 4
- DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 DiabetesRecruitingNCT06983054Phase 4
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney DiseaseRecruitingNCT06982079Phase 3
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory FailureRecruitingNCT06955260Phase 3
- Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudyEnrolling by invitationNCT06954090Phase 4
- Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized StudyRecruitingNCT06929169Phase 2
- Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?Not yet recruitingNCT06922656Phase 4
- Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic AscitesNot yet recruitingNCT06919523Phase 2
- Dapagliflozin for Long COVID SyndromeNot yet recruitingNCT06907251Phase 3
- Impact of Dapagliflozin in Anemic Chronic Kidney Disease PatientsRecruitingNCT06897605Phase 2
- A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesRecruitingNCT06894784Phase 3
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)RecruitingNCT06887062Phase 2
- Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationRecruitingNCT06862739Phase 4
- SGLT2 Inhibitor Utilization Re-perfusion TherapyNot yet recruitingNCT06858436Phase 4
- The EMPA-FIT StudyRecruitingNCT06846411Phase 4
- Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKDNot yet recruitingNCT06820567Phase 3
- A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)RecruitingNCT06785116Phase 4
- Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in ObesityRecruitingNCT06782139Phase 4
- CAMEO-FONTAN -Dapagliflozin in the Failing Fontan CirculationRecruitingNCT06762964Phase 2
- Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With ObesityRecruitingNCT06745063Phase 2
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruitingNCT06742723Phase 3
- Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes MellitusRecruitingNCT06729996Phase 2
- EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined SourceRecruitingNCT06715449Phase 2/3
- Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based ChemotherapyRecruitingNCT06711185Phase 3
- Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type IIRecruitingNCT06706791Phase 4
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinRecruitingNCT06677060Phase 3
- SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) TrialRecruitingNCT06674109Phase 4
- Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status TrialRecruitingNCT06668389Phase 4
- Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE PreventionRecruitingNCT06653738Phase 3
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy AdultsNot yet recruitingNCT06644404Phase 1
- Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of AgeNot yet recruitingNCT06643442Phase 2
- A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus PatientsRecruitingNCT06642623Phase 4
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordRecruitingNCT06642272Phase 4
- The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with MethotrexateNot yet recruitingNCT06641128Phase 4
- Dapagliflozin in Allo-HCT for aGVHDRecruitingNCT06626737Phase 2
- Randomized Trial of SGLT2i in Heart Transplant RecipientsRecruitingNCT06625073Phase 4
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 DiabetesRecruitingNCT06613854Phase 4
- Dapagliflozin in Mangement of Pulmonary Hypertension PatientsNot yet recruitingNCT06612086Phase 1
- Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment PatientsNot yet recruitingNCT06606093Phase 3
- Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)RecruitingNCT06600178Phase 1
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathyRecruitingNCT06580717Phase 4
- To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy AdultsRecruitingNCT06578676Phase 1
- Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary SyndromeRecruitingNCT06576375Phase 3
- Feasibility Trial for a Right Ventricular Failure Platform TrialRecruitingNCT06570473Phase 2
- STunning in Acute Myocardial Infarction - BASRecruitingNCT06562582Phase 4
- Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney TransplantationRecruitingNCT06560801Phase 4
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseaseRecruitingNCT06528405Phase 2
- Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter AblationRecruitingNCT06528262Phase 4
- Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection FractionNot yet recruitingNCT06510270Not applicable
- Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart FailureRecruitingNCT06507657Early Phase 1
- Empagliflozin Reversal of Arterial StiffnEss in AgingRecruitingNCT06506422Phase 2/3
- Cardiotoxicity in Breast Cancer PatientsRecruitingNCT06491680Phase 4
- Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsRecruitingNCT06483074Phase 2
- Efficacy of SGLT2 Inhibitors in Adults With SepsisRecruitingNCT06473844Not applicable
- Prevention of Progression of Prediabetes, Obesity and CV RiskRecruitingNCT06446531Phase 1
- SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HFNot yet recruitingNCT06442280Phase 4
- Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 DiabetesRecruitingNCT06435156Phase 2
- IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron DeficiencyNot yet recruitingNCT06434025Phase 3
- Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic CardiomyopathyRecruitingNCT06433050Early Phase 1
- Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSeaseRecruitingNCT06430684Early Phase 1
- Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced CardiotoxicityRecruitingNCT06427226Phase 2
- Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease PatientsRecruitingNCT06421870Phase 3
- DapagliFLOzin in Renal AL Amyloidosis (FLORAL)RecruitingNCT06420167Phase 2
- Use of SGLT2i in noHCM With HFpEFRecruitingNCT06401343Phase 4
- Enavogliflozin vs. Pioglitazone on Glucose and AtherosclerosisRecruitingNCT06399835Phase 4
- Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis PatientsRecruitingNCT06398977Not applicable
- The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis PatientsRecruitingNCT06365541Phase 4
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes MellitusRecruitingNCT06364930Phase 4
- Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver DiseaseRecruitingNCT06355310Phase 2
- The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection FractionNot yet recruitingNCT06350487Phase 4
- Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced CardiotoxicityRecruitingNCT06341842Phase 2
- Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai VolunteersNot yet recruitingNCT06337409Phase 1
- A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting ConditionsNot yet recruitingNCT06308679Phase 1
- CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIALRecruitingNCT06304857Phase 3
- Mechanism of SGLT2 Inhibition in the KidneyRecruitingNCT06291155Phase 4
- Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary SyndromesRecruitingNCT06286878Phase 2/3
- Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary SyndromeNot yet recruitingNCT06256289Phase 4
- EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal DiseaseRecruitingNCT06249945Phase 4
- Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal DiseaseRecruitingNCT06249932Phase 4
- Ketones, SGLT2, HFrEFRecruitingNCT06229678Early Phase 1
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney DiseaseRecruitingNCT06217302Phase 3
- Treatment of Patients With Diabetic Kidney DiseaseNot yet recruitingNCT06187493Not applicable
- Canagliflozin in Advanced Renal Disease With MRI EndpointsRecruitingNCT06182839Phase 2
- Dapagliflozin in STEMIRecruitingNCT06174753Phase 3
- SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney DiseaseRecruitingNCT06155604Phase 2
- To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated CirrhosisNot yet recruitingNCT06147518Not applicable
- Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxiaNot yet recruitingNCT06147232Phase 2
- SGLT2 Inhibitors in Patients With ADHF During Ventilator WeaningRecruitingNCT06142474Phase 3
- Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes MellitusNot yet recruitingNCT06141980Phase 3
- Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant RecipientsRecruitingNCT06140537Phase 4
- Assessment of Safety and Efficacy of SGLT2is Among LN PatientsNot yet recruitingNCT06113900Phase 1/2
- Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKDRecruitingNCT06110130Phase 4
- Cardioprotective Empagliflozin for Cancer Patients Receiving DoxorubicinNot yet recruitingNCT06103279Phase 2/3
- Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes MellitusNot yet recruitingNCT06098625Not applicable
- Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes MellitusRecruitingNCT06095492Not applicable
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesRecruitingNCT06082063Phase 3
- dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized EvaluationNot yet recruitingNCT06072326Phase 2
- Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With HypertensionRecruitingNCT06055452Phase 4
- SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With PrediabetesRecruitingNCT06054035Phase 4